Equities research analysts at Maxim Group assumed coverage on shares of Actinium Pharmaceuticals Inc (AMEX:ATNM) in a report released on Thursday. The firm set a “buy” rating and a $3.00 price target on the stock.

Actinium Pharmaceuticals (AMEX:ATNM) traded up 0.475% during midday trading on Thursday, reaching $0.635. 257,517 shares of the company traded hands. The firm’s market capitalization is $50.81 million. Actinium Pharmaceuticals has a 12 month low of $0.54 and a 12 month high of $2.15. The firm’s 50 day moving average price is $0.64 and its 200 day moving average price is $1.17.

COPYRIGHT VIOLATION NOTICE: “Actinium Pharmaceuticals Inc (ATNM) Research Coverage Started at Maxim Group” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/09/14/actinium-pharmaceuticals-inc-atnm-research-coverage-started-at-maxim-group.html.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Receive News & Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.